The evidence landscape in precision medicine

Spencer Phillips Hey; Cory V Gerlach; Garrett Dunlap; Vinay Prasad; Aaron S Kesselheim

doi:10.1126/scitranslmed.aaw7745

The evidence landscape in precision medicine

Sci Transl Med. 2020 Apr 22;12(540):eaaw7745. doi: 10.1126/scitranslmed.aaw7745.

Authors

Spencer Phillips Hey^{1

2}, Cory V Gerlach^{3

4

5}, Garrett Dunlap^{3

6}, Vinay Prasad⁷, Aaron S Kesselheim^{8

2}

Affiliations

¹ Harvard Center for Bioethics, Harvard Medical School, Boston, MA, USA. spencer_hey@hms.harvard.edu.
² Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
³ Harvard Program in Therapeutic Sciences, Harvard Medical School, Boston, MA, USA.
⁴ Department of Medicine, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁵ Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
⁶ Program in Biological and Biomedical Sciences, Harvard Medical School, Boston, MA, and Therapeutics Graduate Program, Harvard Medical School, Boston, MA, USA.
⁷ Division of Hematology and Medical Oncology, Knight Cancer Institute, Department of Preventive Medicine and Public Health, and Center for Health Care Ethics, Oregon Health and Science University, Portland, OR, USA.
⁸ Harvard Center for Bioethics, Harvard Medical School, Boston, MA, USA.

PMID: 32321867
DOI: 10.1126/scitranslmed.aaw7745

Abstract

Precision medicine is beginning to make an impact on the treatment of different diseases, but there are still challenges that must be overcome, such as the complexity of interventions, the need for marker validation, and the level of evidence necessary to demonstrate effectiveness. In this Perspective, we describe how evidence landscapes can help to address these challenges.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Precision Medicine*